Ali Yasmine, Monini Caterina, Russeil Etienne, Létang Jean Michel, Testa Etienne, Maigne Lydia, Beuve Michael
Institut de Physique des 2 Infinis de Lyon, Université Claude Bernard Lyon 1, CNRS/IN2P3, 4 rue Enrico Fermi, 69622 Villeurbanne, France.
Laboratoire de Physique de Clermont, Université Clermont Auvergne, CNRS/IN2P3, 4 Avenue Blaise Pascal, 63178 Aubière, France.
Cancers (Basel). 2022 Mar 25;14(7):1667. doi: 10.3390/cancers14071667.
For the evaluation of the biological effects, Monte Carlo toolkits were used to provide an RBE-weighted dose using databases of survival fraction coefficients predicted through biophysical models. Biophysics models, such as the mMKM and NanOx models, have previously been developed to estimate a biological dose. Using the mMKM model, we calculated the saturation corrected dose mean specific energy z1D* (Gy) and the dose at 10% for human salivary gland (HSG) cells using Monte Carlo Track Structure codes LPCHEM and Geant4-DNA, and compared these with data from the literature for monoenergetic ions. These two models were used to create databases of survival fraction coefficients for several ion types (hydrogen, carbon, helium and oxygen) and for energies ranging from 0.1 to 400 MeV/n. We calculated values as a function of LET with the mMKM and the NanOx models, and compared these with the literature. In order to estimate the biological dose for SOBPs, these databases were used with a Monte Carlo toolkit. We considered GATE, an open-source software based on the GEANT4 Monte Carlo toolkit. We implemented a tool, the BioDoseActor, in GATE, using the mMKM and NanOx databases of cell survival predictions as input, to estimate, at a voxel scale, biological outcomes when treating a patient. We modeled the HIBMC 320 MeV/u carbon-ion beam line. We then tested the BioDoseActor for the estimation of biological dose, the relative biological effectiveness (RBE) and the cell survival fraction for the irradiation of the HSG cell line. We then tested the implementation for the prediction of cell survival fraction, RBE and biological dose for the HIBMC 320 MeV/u carbon-ion beamline. For the cell survival fraction, we obtained satisfying results. Concerning the prediction of the biological dose, a 10% relative difference between mMKM and NanOx was reported.
为了评估生物效应，使用蒙特卡罗工具包，通过生物物理模型预测的存活分数系数数据库来提供RBE加权剂量。此前已经开发了诸如mMKM和NanOx模型等生物物理模型来估算生物剂量。使用mMKM模型，我们使用蒙特卡罗径迹结构代码LPCHEM和Geant4-DNA计算了人唾液腺（HSG）细胞的饱和校正剂量平均比能z1D*（Gy）和10%存活率时的剂量，并将这些结果与文献中关于单能离子的数据进行了比较。这两个模型用于创建几种离子类型（氢、碳、氦和氧）以及能量范围从0.1到400 MeV/n的存活分数系数数据库。我们用mMKM和NanOx模型计算了作为传能线密度函数的 值，并与文献进行了比较。为了估算扩展布拉格峰（SOBP）的生物剂量，这些数据库与一个蒙特卡罗工具包一起使用。我们考虑了基于GEANT4蒙特卡罗工具包的开源软件GATE。我们在GATE中实现了一个工具BioDoseActor，使用细胞存活预测的mMKM和NanOx数据库作为输入，以在体素尺度上估算治疗患者时的生物结果。我们对HIBMC 320 MeV/u碳离子束线进行了建模。然后我们测试了BioDoseActor对HSG细胞系照射的生物剂量、相对生物效能（RBE）和细胞存活分数的估算。然后我们测试了该实现对HIBMC 320 MeV/u碳离子束线的细胞存活分数、RBE和生物剂量预测的情况。对于细胞存活分数，我们获得了令人满意的结果。关于生物剂量的预测，报告了mMKM和NanOx之间存在10%的相对差异。
